APR 01, 2015 03:44 PM PDT

Experimental Cancer Drug Restores Memory in Mouse Model of Alzheimer's

Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug, Yale School of Medicine researchers reported in the journal Annals of Neurology.
Star-like glial cells in red surround alpha beta plaques in the cortex of a mouse with a model of Alzheimer's Disease.
The drug, AZD05030, developed by Astra Zeneca proved disappointing in treating solid tumors but appears to block damage triggered during the formation of amyloid-beta plaques, a hallmark of Alzheimer's disease. The new study, funded by an innovative National Institutes of Health (NIH) program to test failed drugs on different diseases, has led to the launch of human trials to test the efficacy of AZD05030 in Alzheimer's patients.

"With this treatment, cells under bombardment by beta amyloid plaques show restored synaptic connections and reduced inflammation, and the animal's memory, which was lost during the course of the disease, comes back," said Stephen M. Strittmatter, the Vincent Coates Professor of Neurology and senior author of the study.

In the last five years, scientists have developed a more complete understanding of the complex chain of events that leads to Alzheimer's disease. The new drug blocks one of those molecular steps, activation of the enzyme FYN, which leads to the loss of synaptic connections between brain cells. Several other steps in the disease process have the potential to be targets for new drugs, Strittmatter said.

"The speed with which this compound moved to human trials validates our New Therapeutic Uses program model and serves our mission to deliver more treatments to more patients more quickly," said Dr. Christopher P. Austin, director of NIH's National Center for Advancing Translational Sciences (NCATS), which funded the work.

Yale's Christopher H. van Dyck, a co-author of the paper, and Strittmatter have initiated a multi-site clinical trial to determine whether the drug can also benefit Alzheimer's patients.

Source: Yale University
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 17, 2019
Health & Medicine
SEP 17, 2019
Caffeine Users are More Sensitive to the Smell of Coffee
Are you a coffee addict? Your sense of smell may be fine-tuned to the caffeinated beverage’s aroma. New research has provided new evidence that frequ...
SEP 17, 2019
Health & Medicine
SEP 17, 2019
Are Anxiety Disorders Affected by Regulation of Intestinal Microbiota?
Our understanding of the gut-brain axis has increased significantly in the past decade with strong support by recent studies of the bidirectional natu...
SEP 17, 2019
Technology
SEP 17, 2019
Artificial Intelligence May Soon Detect Brain Aneurysms
Artificial intelligence (AI) may soon help doctors diagnose brain aneurysms which are bulges in blood vessels that can lead to stroke, brain damage, and de...
SEP 17, 2019
Neuroscience
SEP 17, 2019
Smartphone-controlled brains?
A team of scientists in Korea and the United States have developed a tiny, flexible, wireless device that can control neurons and neural circuits in the mo...
SEP 17, 2019
Health & Medicine
SEP 17, 2019
How Much Caffeine Can Trigger a Migraine?
Do you suffer from migraines? Your caffeine intake may be a trigger. Researchers from the Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women&r...
SEP 17, 2019
Genetics & Genomics
SEP 17, 2019
Can Lifestyle Changes Switch Off Dementia Genes?
Around 50 million people have dementia worldwide, with 10 million new cases emerging each year (World Health Organization: 2019). Most prominent in people ...
Loading Comments...